Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal for Immunotherapy of Cancer|October 6, 2022
Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case reportMaxwell J Kroloff, Josefin-Beate Holz, Omer Stern, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 15, 2010
Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cellsPrakash K Rao, Edoardo Missiaglia, Lauren Shields, et al.
The Prostate|April 10, 2008
Expression profiling of CD133+ and CD133- epithelial cells from human prostateChristopher J Shepherd, Siân Rizzo, Ioanna Ledaki, et al.
Differentiation; Research in Biological Diversity|January 25, 2007
A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiationBernadette Daly-Burns, Tahirah N Alam, Alan Mackay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.
JAMA Oncology|August 30, 2019
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical TrialPeter Schmid, Matthias Zaiss, Catherine Harper-Wynne, et al.
Pageof 1